Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Sep. 4, 2026-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th, at 10:55 AM ET Format: Presentation & 1x1’s Location: NYC, NY Webcast Link: Here About Gossamer Bio Gossamer Bio is a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with pulmonary hypertension. View source version on businesswire.com: https://www.businesswire.com/news/home/20260904867053/en/ For Investors and Media Bryan Giraudo, Chief Financial Officer & Chief Operating Officer Gossamer Bio Investor Relations ir@gossamerbio.com Source: Gossamer Bio, Inc.